par Gouvêa Bogossian, Elisa
;Kempen, Bavo;Veldeman, Michael;Park, Soojin;Rass, Verena;Marinesco, Stephane;Weiss, Miriam;Schubert, Gerrit Alexander;Kastenholz, Nick;Claassen, Jan;Kindl, Philipp;Berek, Anna;Anderloni, Marco;Conzen-Dilger, Catharina;Schuind, Sophie
;Balança, Baptiste;Tholance, Yannick;Connolly, Edward Sander;Meyfroidt, G.;Helbok, Raimund;Carra, Giorgia;Taccone, Fabio Silvio 
Référence Intensive care medicine, 51, 4, page (708-720), 107259
Publication Publié, 2025-04-01



Référence Intensive care medicine, 51, 4, page (708-720), 107259
Publication Publié, 2025-04-01
Article révisé par les pairs
Résumé : | Purpose: Brain tissue hypoxia and metabolic dysfunction are common in patients with subarachnoid hemorrhage (SAH) and may worsen prognosis. We aimed to assess the impact of episodes of low brain tissue partial pressure of oxygen (PbtO2) and metabolic dysfunction (elevated lactate pyruvate ratio—LPR measured by cerebral microdialysis, CMD) on neurological outcome at 6 months. Methods: This is a multicentric retrospective cohort study of SAH patients admitted to 5 neurocritical care units who required invasive multimodal neuromonitoring. The relationship between episodes of low PbtO2 combined with elevated LPR and 6-month Glasgow Outcome Scale (GOS) was visualized in a color-coded plot. We performed a multivariate analysis of the association between the percentage of time spent with the low PbtO2 and/or high LPR and neurological outcome and mortality at 6 months. Results: We included 232 SAH patients with a median of 117 (IQR 77–154) h of monitoring per patient. The color-coded plot illustrated that combined episodes of low PbtO2 and elevated LPR were prevalent in patients with unfavorable neurological outcome (e.g., GOS 1–3). This association was less evident in patients with isolated low PbtO2 or isolated elevated LPR. In a multivariate model, the cumulative PbtO2/LPR burden was independently associated with unfavorable neurological outcome. Conclusions: In this study, low PbtO2 and metabolic insults were more prevalent among SAH patients with unfavorable long-term neurological outcome at 6 months. The role of multimodal neuromonitoring in guiding therapies and potentially influencing the outcome of these patients warrants further studies. |